The University of California, San Diego (UCSD) Moores Cancer Center has received a significant donation from Pfizer to launch an initiative focused on early detection and prevention of cancer. The partnership, which will be led by the Moores Cancer Center, aims to improve cancer screening and prevention in the community, particularly in areas with limited access to healthcare. The initiative will focus on strategies to increase participation in evidence-based screening approaches for various types of cancer, including colorectal, breast, cervical, and prostate cancers.
The partnership will also involve the collection and management of data and biospecimens to study key scientific questions related to cancer. The initiative will be implemented through a community outreach program, which will leverage established networks with Federally Qualified Health Centers throughout the county.
The goal of the initiative is to increase the chances of successful treatment by identifying cancer at its earliest stages, leading to better patient outcomes. The partnership with Pfizer will also help to promote collaboration between industry partners and the Moores Cancer Center to streamline pathways for early detection, discovery, and treatment of cancer.
According to Dr. Diane Simeone, Director of the Moores Cancer Center, the initiative represents the future of oncology and has the potential to significantly improve the effectiveness of cancer treatments. Jeffrey Settleman, Chief Scientific Officer for Oncology Research and Development at Pfizer, noted that the company’s partnership with the Moores Cancer Center is part of its efforts to improve access to quality cancer care for everyone.
The initiative is expected to have a significant impact on the community, particularly in underserved areas where access to healthcare is limited. It is an example of the potential for collaboration between academia and industry to improve healthcare outcomes and save lives.